Billionaire entrepreneur Mark Cuban recently shared his views on artificial intelligence (AI) and cybersecurity. Speaking at the Reuters Total Health conference, he emphasized that he doesn’t think AI poses a great threat. Instead, he believes that organizations can protect themselves from AI-driven cyberattacks by using similar technology for their defense.
Cuban introduced a concept he calls the “Cockroach Theory” of cybersecurity, likening harmful AI agents to pesky household insects. He explained, “I’m not a doomer at all. While we often hear about the worst-case scenarios related to AI, we rarely discuss how this same powerful AI can help defend against those threats.”
He illustrated his point using the analogy of a newly built house. “When you build a new home, you call pest control to spray for cockroaches. But even then, it’s hard to keep them out completely because there are so many of them. If one gets in, more will follow,” Cuban explained. In this way, he compares the infiltration of AI into systems to the way cockroaches find their way into homes.
Cuban said that if malicious actors create numerous autonomous agents to attack systems, defenders can use the same level of AI technology to protect against these attacks. “If someone can create enough malicious agents that manage to penetrate a system, there’s a way to counter that with equally powerful AI,” he noted. He added that the effort to tackle these threats would likely increase from those working to defend the systems.
In addition to his insights on AI, Cuban also talked about his healthcare initiative, Cost Plus Drug Company. Launched in 2022 to lower pharmaceutical costs, the company operates transparently by charging the wholesale price of medications plus a fixed 15% markup. Recently, Cost Plus joined TrumpRx.gov to distribute discounted weight-loss drugs.
Cuban highlighted that his company has expanded from retail to manufacturing, starting in 2025 when it began producing sterile injectable medications that hospitals often need. He also announced the development of mobile manufacturing units he calls “pods.” These units, the size of tractor-trailers, can work independently or connect with others to produce both generic medications and specialized treatments for rare diseases.
